Retatrutide (LY3437943) is an investigational once-weekly injectable triple agonist that simultaneously activates three receptors: GLP-1, GIP, and glucagon (GCG).
Does Retatrutide help with weight loss?
Retatrutide helps with weight loss and the data shows it is highly effective, how then?
GLP-1 receptor activation: Slows gastric emptying, signals brain satiety centers to reduce appetite and food intake, and enhances glucose-dependent insulin secretion while suppressing glucagon from the pancreas.
GIP receptor activation (most potent component): Boosts insulin release, improves fat metabolism/processing, and supports overall appetite regulation and glycemic control; may also mitigate some GI side effects.
Glucagon receptor activation: Increases energy expenditure (thermogenesis/resting metabolic rate), promotes lipolysis and hepatic fatty acid oxidation (fat burning), and reduces liver fat/lipogenesis—driving calorie burn beyond what diet alone achieves.
Synergistic result: Strong reduction in caloric intake (via appetite suppression + prolonged satiety) combined with elevated energy expenditure (via glucagon), leading to substantial fat loss. In phase 2 trials, the 12 mg dose achieved ~24% mean weight reduction at 48 weeks, with ongoing loss and no plateau.
Retatrutide Peptide Benefits
Substantial weight loss: Up to 24.2% mean loss at 48 weeks (phase 2, 12 mg dose); up to 28.7% (71 lbs) at 68 weeks in phase 3 TRIUMPH-4 (obesity + knee osteoarthritis, 12 mg); up to 16.8% (37 lbs) at 40 weeks in phase 3 diabetes trial. No plateau observed—weight loss continues.
Improved glycemic control (in type 2 diabetes): A1C reduction up to 2.0% at 40 weeks (vs. ~0.8% placebo); many achieve A1C <6.5% or even <5.7%.
Liver fat reduction (MASLD/NAFLD): Up to 82–86% relative reduction at 24 weeks (8–12 mg); normal liver fat (<5%) achieved in up to 86% of patients. Strong improvements in liver enzymes and potential for early disease resolution.
Cardiometabolic improvements: Reductions in blood pressure, triglycerides, non-HDL cholesterol, fasting glucose, and insulin resistance; favorable lipid profile changes.
Body composition and function: Significant fat mass loss (including visceral/abdominal fat); proportion of lean mass loss similar to other incretin drugs. In osteoarthritis trial: substantial pain reduction (up to 75.8% on WOMAC score) and better physical function/mobility.
Other reported benefits: Increased satiety, reduced appetite and food intake, improved energy levels, mobility, self-confidence, and quality of life; participants often report feeling more in control of eating.
Benefits are dose-dependent (strongest at 8–12 mg). It is still investigational (phase 3 ongoing; not FDA-approved). Gastrointestinal side effects are common but mostly mild-moderate and similar to other GLP-1/GIP drugs. Always discuss with a physician for individual risks/benefits.
Where to inject Retatrutide for best results?
Abdomen (most common and preferred): At least 2 inches (5 cm) away from the belly button, in areas with subcutaneous fat. Rotate sides.
Upper thigh (front/outer): Upper outer part, about a hand’s width above the knee or below the hip.
Upper arm (back/posterior, triceps area): Harder for self-injection; may need help.
Key rules:
Rotate sites each week to prevent irritation or lumps.
Clean the site with alcohol.
Avoid bruised, red, tender, scarred, or hard areas.
Pinch skin, insert needle at 45–90° angle (depending on fat thickness), inject slowly, hold for ~5 seconds.
Absorption and effectiveness are similar across sites (based on related GLP-1/GIP data). Abdomen is easiest for most. Retatrutide remains investigational (not FDA-approved); follow exact instructions from your provider or trial protocol, as formulation may be vial + syringe or pen. Consult a healthcare professional for technique demonstration.
Retatrutide Peptide Side Effects
Retatrutide side effects (primarily from phase 2 and phase 3 TRIUMPH trials, especially TRIUMPH-4):Most common (dose-dependent, mostly mild-moderate, occur mainly during dose escalation):
- Nausea: 38–43% (9–12 mg) vs ~11% placebo
- Diarrhea: 33–35% vs ~13% placebo
- Constipation: 22–25% vs ~9% placebo
- Vomiting: 20–21% vs ~0% placebo
- Decreased appetite: ~18–19% vs ~9% placebo
These GI effects are transient for most people and partially reduced with slower dose escalation (starting at 2 mg).Notable additional side effect:
- Dysesthesia (abnormal sensations like tingling, altered touch): 9–21% (dose-dependent, 8.8% at 9 mg, 20.9% at 12 mg) vs 0.7% placebo. Generally mild and rarely caused discontinuation.
Other effects:
- Increased heart rate: Dose-dependent rise (typically 5–10+ bpm), peaks around week 24, then declines.
- Overall adverse event rates: 73–94% (higher at top doses) vs ~70% placebo.
What happens when you stop Retatrutide?
When you stop retatrutide, expect significant weight regain and reversal of most benefits, similar to other GLP-1/GIP/glucagon agonists.What happens:
Weight regain: Typically 60–80% of lost weight returns within 12 months (e.g., ~2/3 like semaglutide data). For retatrutide’s ~24% loss, this means regaining ~14–19% body weight. Regain starts within 4–8 weeks, accelerates initially, then slows/plateaus after ~1 year. Some may retain ~20–40% of loss long-term with intensive lifestyle changes; most do not without ongoing intervention. Specific retatrutide discontinuation data is limited (phase 2/3 trials focused on on-treatment results; dedicated maintenance extensions ongoing).
Appetite and hunger: Returns rapidly (often stronger initially) as GLP-1/GIP satiety signaling stops and glucagon-driven energy expenditure drops. Increased “food noise” and caloric intake.
Cardiometabolic effects: Blood sugar, A1C, blood pressure, lipids, and insulin sensitivity largely revert toward baseline within 1–2 years. Liver fat reduction reverses.
Other: Possible temporary metabolic slowdown; any improvements in energy, mobility, or osteoarthritis symptoms fade.
Why? Obesity is chronic, retatrutide overrides biological defenses (hunger hormones, lower metabolism, set-point regulation) only while active. Stopping removes this override.